Canada FR EN

Fresenius Kabi around the world

Africa & Middle East
- MENA
- South Africa
Asia Pacific
- Australia
- China
- China (Hong Kong SAR)
- India
- Indonesia
- Japan
- Korea
- Malaysia
- New Zealand
- Philippines
- Singapore
- Taiwan
- Thailand
- Vietnam
Europe
- Austria
- Belgium
- Croatia
- Czech Republic
- Denmark
- Finland
- France
- Germany
- Great Britain
- Hungary
- Ireland
- Italy
- Netherlands
- Norway
- Poland
- Portugal
- Romania
- Russian Federation
- Slovakia
- Spain
- Sweden
- Switzerland
Latin America
- Argentina
- Brazil
- Chile
- Colombia
- Ecuador
- Mexico
- Peru
North America
- Canada
- USA

Company
- Main menu Company
  Learn about Fresenius Kabi both globally and locally
  - Company About Us
    About Us page
Products & Services
- Main menu Products & Services
  Discover Fresenius Kabi Canada's Products & Services
  - Products & Services Biosimilars
    Biosimilars section
  - Products & Services IV Drugs
    IV Drugs section
  - Products & Services Medical Nutrition
    Parenteral Nutrition section
  - Products & Services Animal Health
    Animal Health section
  - Products & Services Colloids
    Colloids
  - Products & Services Infusion Technology
    Infusion Technology section
  - Products & Services Transfusion Technology
    Transfusion Technology section
  - Products & Services Compounding
    Compounding
  - Products & Services Standard Solutions
    Standard Solutions section
Careers
- Main menu Careers
  Careers page

Important Safety Information Bacitracin for Injection (50,000 IU per vial) – Risk of Nephrotoxicity and Anaphylactic Reactions

December 19, 2020